临床与病理杂志2024，Vol.44Issue(3)：434-441,8.DOI:10.11817/j.issn.2095-6959.2024.240038
肺腺癌基因突变的研究进展
Research progress on gene mutations in lung adenocarcinoma
宋晓宇 1郝俊梅1
作者信息
- 1. 滨州医学院烟台附属医院病理科,山东烟台 264100
- 折叠
摘要
Abstract
The common driver genes om lung adenocarcinoma mainly include epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase(ALK),Kirsten rat sarcoma virus oncogene homology(KRAS),and c-ros proto-oncogene 1 tyrosine kinase(ROS1).In recent years,with the deepening of research on molecular signaling pathways,targeted therapy based on molecular markers and molecular typing has made great progress,gradually changing the treatment model into precision therapy guided by diver genes.Although the effects of targeted therapy are significant,almost all patients develop resistance after 6 months to 1 year of treatment.Immunotherapy is currently another research hotspot.Although immunotherapy takes effect slowly,its effects are long-lasting,which can complement targeted therapy.The combination of the two is a promising approach for overcoming resistance in treatment.关键词
肺腺癌/基因突变/驱动基因/预后/靶向治疗Key words
lung adenocarcinoma/gene mutation/driver gene/prognosis/targeted therapy引用本文复制引用
宋晓宇,郝俊梅..肺腺癌基因突变的研究进展[J].临床与病理杂志,2024,44(3):434-441,8.
